Jonathan Brouillette

Dr. Jonathan Brouillette


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
AHAudrey Hector
Audrey Hector
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette
Soluble amyloid-beta oligomers (Aβo) start to accumulate in the human brain one to two decades before any clinical symptoms of Alzheimer's disease (AD) and are implicated in synapse loss, one of the best predictors of memory decline that characterize the illness. Cognitive impairment in AD was traditionally thought to result from a reduction in synaptic activity which ultimately induces neurodegeneration. More recent evidence indicates that in the early stages of AD synaptic failure is, at least partly, induced by neuronal hyperactivity rather than hypoactivity. Here, we review the growing body of evidence supporting the implication of soluble Aβo on the induction of neuronal hyperactivity in AD animal models, in vitro, and in humans. We then discuss the impact of Aβo-induced hyperactivity on memory performance, cell death, epileptiform activity, gamma oscillations, and slow wave activity. We provide an overview of the cellular and molecular mechanisms that are emerging to explain how Aβo induce neuronal hyperactivity. We conclude by providing an outlook on the impact of hyperactivity for the development of disease-modifying interventions at the onset of AD.

24 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JDJulien Dufort-Gervais
Julien Dufort-Gervais
CPChloé Provost
Chloé Provost
LCLaurence Charbonneau
Laurence Charbonneau
CNChristopher M. Norris
Christopher M. Norris
FCFrédéric Calon
Frédéric Calon
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette
Synapse loss occurs early and correlates with cognitive decline in Alzheimer’s disease (AD). Synaptotoxicity is driven, at least in part, by amyloid-beta oligomers (Aβo), but the exact synaptic components targeted by Aβo remain to be identified. We here tested the hypotheses that the post-synaptic protein Neuroligin-1 (NLGN1) is affected early in the process of neurodegeneration in the hippocampus, and specifically by Aβo, and that it can modulate Aβo toxicity. We found that hippocampal NLGN1 was decreased in patients with AD in comparison to patients with mild cognitive impairment and control subjects. Female 3xTg-AD mice also showed a decreased NLGN1 level in the hippocampus at an early age (i.e., 4 months). We observed that chronic hippocampal Aβo injections initially increased the expression of one specific Nlgn1 transcript, which was followed by a clear decrease. Lastly, the absence of NLGN1 decreased neuronal counts in the dentate gyrus, which was not the case in wild-type animals, and worsens impairment in spatial learning following chronic hippocampal Aβo injections. Our findings support that NLGN1 is impacted early during neurodegenerative processes, and that Aβo contributes to this effect. Moreover, our results suggest that the presence of NLGN1 favors the cognitive prognosis during Aβo-driven neurodegeneration.

1 April 2019 in Neurobiology of Learning and Memory
Verified
Journal Article
Closed access
JDJulien Dufort-Gervais
Julien Dufort-Gervais
Valerie MongrainValerie Mongrain
Valerie Mongrain
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette

7 July 2023 in Frontiers in Neuroscience
Verified
Journal Article
Open access
DLDaniel Lamontagne-Kam
Daniel Lamontagne-Kam
AUAnosha Kiran Ulfat
Anosha Kiran Ulfat
VHVincent Hervé
Vincent Hervé
TVTra-My Vu
Tra-My Vu
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette
Propagation of tau fibrils correlate closely with neurodegeneration and memory deficits seen during the progression of Alzheimer’s disease (AD). Although it is not well-established what drives or attenuates tau spreading, new studies on human brain using positron emission tomography (PET) have shed light on how tau phosphorylation, genetic factors, and the initial epicenter of tau accumulation influence tau accumulation and propagation throughout the brain. Here, we review the latest PET studies performed across the entire AD continuum looking at the impact of amyloid load on tau pathology. We also explore the effects of structural, functional, and proximity connectivity on tau spreading in a stereotypical manner in the brain of AD patients. Since tau propagation can be quite heterogenous between individuals, we then consider how the speed and pattern of propagation are influenced by the starting localization of tau accumulation in connected brain regions. We provide an overview of some genetic variants that were shown to accelerate or slow down tau spreading. Finally, we discuss how phosphorylation of certain tau epitopes affect the spreading of tau fibrils. Since tau pathology is an early event in AD pathogenesis and is one of the best predictors of neurodegeneration and memory impairments, understanding the process by which tau spread from one brain region to another could pave the way to novel therapeutic avenues that are efficient during the early stages of the disease, before neurodegeneration induces permanent brain damage and severe memory loss.

1 April 2018 in Current Biology
Verified
Journal Article
Closed access
DCDavid Castonguay
David Castonguay
JDJulien Dufort-Gervais
Julien Dufort-Gervais
CMCaroline Ménard
Caroline Ménard
MCManavi Chatterjee
Manavi Chatterjee
RQRémi Quirion
Rémi Quirion
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette

26 December 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
AHAudrey Hector
Audrey Hector
CMChristina McAnulty
Christina McAnulty
MPMaude‐Éloïse Piché‐Lemieux
Maude‐Éloïse Piché‐Lemieux
CAClaire Alves‐Pires
Claire Alves‐Pires
VBValérie Buée‐Scherrer
Valérie Buée‐Scherrer
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette
Tau hyperphosphorylation is a major neuropathological hallmark of many neurodegenerative disorders such as Alzheimer’s disease. Several anesthetics have been shown previously to induced marked tau hyperphosphorylation. Although the ketamine/xylazine mixture is one of the most commonly used anesthetic agents in animal research and veterinary practice, the effect of this anesthetic agent on tau phosphorylation still remains to be determined. Here, we found that ketamine‐/xylazine‐induced a rapid and robust hyperphosphorylation of tau in a dose‐dependent manner under normothermic and hypothermic conditions in mice. When used together, ketamine and xylazine exerted a synergistic action on tau phosphorylation most strongly not only on epitopes S396 and S262, but also on other residues (T181, and S202/T205). We observed that activation of the calmodulin‐dependent protein kinase II (CaMKII) is the major upstream molecular event leading to tau hyperphosphorylation following ketamine/xylazine anesthesia in mice. Moreover, we observed that intracerebroventricular injection of the selective CaMKII inhibitor KN93 attenuated tau hyperphosphorylation. Since ketamine/xylazine also had a marked impact on other key molecular signaling pathways involving the MAP/microtubule affinity‐regulating kinase (MARK), extracellular signal‐regulated kinase (ERK), and glycogen synthase kinase‐3 (GSK3), our study calls for high caution and careful monitoring when using this anesthetic agent in laboratory animal settings across all fields of biological sciences in order to avoid artifactual results.